Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
- PMID: 34412685
- PMCID: PMC8377882
- DOI: 10.1186/s13287-021-02420-8
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Abstract
Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are available including chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHSCT), and receptor-antagonist drugs, the 5-year survival of patients is quietly disappointing, less than 30%. alloHSCT is the major curative approach for AML with promising results but the treatment has severe adverse effects such as graft-versus-host disease (GVHD). Therefore, as an alternative, more efficient and less harmful immunotherapy-based approaches such as the adoptive transferring T cell therapy are in development for the treatment of AML. As such, chimeric antigen receptor (CAR) T cells are engineered T cells which have been developed in recent years as a breakthrough in cancer therapy. Interestingly, CAR T cells are effective against both solid tumors and hematological cancers such as AML. Gradually, CAR T cell therapy found its way into cancer therapy and was widely used for the treatment of hematologic malignancies with successful results particularly with somewhat better results in hematological cancer in comparison to solid tumors. The AML is generally fatal, therapy-resistant, and sometimes refractory disease with a disappointing low survival rate and weak prognosis. The 5-year survival rate for AML is only about 30%. However, the survival rate seems to be age-dependent. Novel CAR T cell therapy is a light at the end of the tunnel. The CD19 is an important target antigen in AML and lymphoma and the CAR T cells are engineered to target the CD19. In addition, a lot of research goes on the discovery of novel target antigens with therapeutic efficacy and utilizable for generating CAR T cells against various types of cancers. In recent years, many pieces of research on screening and identification of novel AML antigen targets with the goal of generation of effective anti-cancer CAR T cells have led to new therapies with strong cytotoxicity against cancerous cells and impressive clinical outcomes. Also, more recently, an improved version of CAR T cells which were called modified or smartly reprogrammed CAR T cells has been designed with less unwelcome effects, less toxicity against normal cells, more safety, more specificity, longer persistence, and proliferation capability. The purpose of this review is to discuss and explain the most recent advances in CAR T cell-based therapies targeting AML antigens and review the results of preclinical and clinical trials. Moreover, we will criticize the clinical challenges, side effects, and the different strategies for CAR T cell therapy.
Keywords: Acute myeloid leukemia; Adoptive cell therapy; Chimeric antigen receptor T cells; Hematological malignancy; Target antigen.
© 2021. The Author(s).
Conflict of interest statement
There is no conflict of interest.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8377882/bin/13287_2021_2420_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8377882/bin/13287_2021_2420_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8377882/bin/13287_2021_2420_Fig3_HTML.gif)
Similar articles
-
Recent advances in CAR-T cell therapy for acute myeloid leukaemia.J Cell Mol Med. 2024 May;28(9):e18369. doi: 10.1111/jcmm.18369. J Cell Mol Med. 2024. PMID: 38712978 Free PMC article. Review.
-
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.Stem Cell Res Ther. 2021 Mar 29;12(1):217. doi: 10.1186/s13287-021-02283-z. Stem Cell Res Ther. 2021. PMID: 33781320 Free PMC article. Review.
-
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.J Immunother Cancer. 2021 Sep;9(9):e003149. doi: 10.1136/jitc-2021-003149. J Immunother Cancer. 2021. PMID: 34531250 Free PMC article.
-
Chimeric antigen receptor T cells for acute myeloid leukemia.Eur J Haematol. 2024 Jan;112(1):28-35. doi: 10.1111/ejh.14047. Epub 2023 Jul 16. Eur J Haematol. 2024. PMID: 37455578 Review.
-
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.J Immunother Cancer. 2022 Jul;10(7):e004222. doi: 10.1136/jitc-2021-004222. J Immunother Cancer. 2022. PMID: 35803613 Free PMC article.
Cited by
-
Recent advances in CAR-T cell therapy for acute myeloid leukaemia.J Cell Mol Med. 2024 May;28(9):e18369. doi: 10.1111/jcmm.18369. J Cell Mol Med. 2024. PMID: 38712978 Free PMC article. Review.
-
Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression.Life (Basel). 2024 Feb 27;14(3):309. doi: 10.3390/life14030309. Life (Basel). 2024. PMID: 38541635 Free PMC article. Review.
-
Gastric cancer and mesenchymal stem cell-derived exosomes: from pro-tumorigenic effects to anti-cancer vehicles.Arch Pharm Res. 2024 Jan;47(1):1-19. doi: 10.1007/s12272-023-01477-8. Epub 2023 Dec 27. Arch Pharm Res. 2024. PMID: 38151649 Review.
-
Broadening the horizon: potential applications of CAR-T cells beyond current indications.Front Immunol. 2023 Nov 27;14:1285406. doi: 10.3389/fimmu.2023.1285406. eCollection 2023. Front Immunol. 2023. PMID: 38090582 Free PMC article. Review.
-
A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.Blood. 2024 Feb 8;143(6):507-521. doi: 10.1182/blood.2023021054. Blood. 2024. PMID: 38048594
References
-
- Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood J Am Soc Hematol. 2016;127:62–70. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials